Wall Street Zen Upgrades Ralliant (NYSE:RAL) to Buy

Ralliant (NYSE:RAL) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other brokerages have also weighed in on RAL. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research note on Wednesday, May 27th. Morgan Stanley boosted their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Citigroup increased their price objective on shares of Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Evercore started coverage on shares of Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $70.80.

Ralliant Price Performance

NYSE:RAL opened at $70.01 on Friday. Ralliant has a 52 week low of $37.27 and a 52 week high of $75.41. The stock’s fifty day moving average is $65.21 and its two-hundred day moving average is $53.15. The company has a market capitalization of $7.84 billion and a P/E ratio of -6.40. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts expect that Ralliant will post 2.64 EPS for the current year.

Institutional Trading of Ralliant

Several hedge funds have recently made changes to their positions in the business. Dodge & Cox grew its holdings in shares of Ralliant by 13.3% in the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock valued at $621,849,000 after purchasing an additional 1,434,376 shares in the last quarter. Viking Global Investors LP acquired a new stake in Ralliant during the 2nd quarter worth approximately $257,200,000. Millennium Management LLC lifted its holdings in Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after buying an additional 3,147,660 shares in the last quarter. State Street Corp purchased a new position in Ralliant in the 2nd quarter valued at approximately $213,096,000. Finally, Invesco Ltd. boosted its position in Ralliant by 4.9% in the 4th quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock valued at $206,674,000 after buying an additional 187,898 shares during the period.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.